The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
Subscribe To Our Newsletter & Stay Updated
